Asia Deal Watch: EpimAb Licenses Bispecific Antibody To Newly Formed Vignette

 
• By Joseph Haas, Dexter Jie Yan, Xu Hu, and Lisa Takagi

Also including deals between EpimAb/Vignette, Allist/Jacobio, Rigel/Kissei, Simcere/TargetRx, Altamira/Nuance, PharmaEssentia/Forus and Chugai/LTL.

Asia Deal Watch
• Source: Alamy
Xu Hu

Read more by Xu Hu

Xu is a senior reporter and covers aspects on policy and regulations in China pharma industry within the APAC Pharma news team.

More from Deal Watch

More from Deals